Dr. Steinherz is a Pediatric Hematologic Oncologist and Director of the Leukemia and Lymphoma Studies at Memorial Sloan-Kettering Cancer Center.He was among the founders of Camp Simcha.During his 30-year tenure at MSKCC, Dr. Steinherz and his colleagues have developed anew treatment protocols that have improved the survival rates of patients with ALL from 50 percent to 80 – 90 percent. He is a member of the Leukemia Strategy Group of the Children’s Cancer Group for more than 20 years.
https://www.mskcc.org/experience/hear-from-patients/jackson ( Jackson’s story)
She was involved in the first cord-blood transplant in the world. Dr. Kurtzberg finds it rewarding to make a difference when treating challenging diseases and feels fortunate to be able to develop new treatments in the laboratory that she can take into the clinic to help patients.
The COG offers clinical trials for children with cancer. This international group has the backing of the U.S. National Cancer Institute and are active in cancer research and follow detailed guidelines and have data to support their treatment decisions. The COG partners with research scientists from around the world in the efforts to understand the causes and to find more effective treatments for cancer. The COG is the most experienced organization in the world in the clinical development of new therapeutics for children and adolescents with cancer. The COG phase 1 and pilot consortium is a limited institution consortium. Comprised of 21 premier pediatric oncologyprograms in the country.
Dr. Kantarjian is Professor and Chairman in the Department of Leukemia as well as the Samsung Distinguished University Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center. He is also a non-resident fellow in health policy at the Rice University Baker Institute. As a clinical- translational researcher, Dr. Kantarjian has contributed to significant improvements in the treatment of various leukemias, including the development and testing of first and second generation BCR-ABL inhibitors in chronic myeloid leukemia, combination therapies for acute lymphocytic leukemia, and several new treatments for acute myeloid leukemia and myelodysplastic syndrome.
St.Jude is the first and only national cancer institute- designated comprehensive cancer center devoted solely to children. St. Jude patients with acute lymphoblastic leukemia have a 94%survival rate, the best worldwide outcomes for this disease. St. Jude Children’s Hospital treats children with many different types of leukemias, including the difficult- to- treat cases. Leukemia is a complex disease and the treatment requires the coordinated care of many experts including pediatric oncologists, surgeons, radiation specialist, radiologists, and other professionals which are the best worldwide in St. Judes.
Dr. Pope is a pediatric hematology-oncology specialist in Charlotte, NC and has been practicing for 13 years now. She has completed her fellowship at Cincinnati Children's Hospital Medical Center and commonly performs the bone marrow biopsy, blood transfusion and chemotherapy for pediatric patients. She is loved by her patient’s who think she is excellent at communicating the long-term care needs with her patients and has a deep heart of compassion.
This is one of the first centers on the globe to use a precision tumor and leukemia DNA sequencing to guide treatment for children and young adults with relapsed and high-risk cancers. At the CBD, the translational and clinical research allows the physicians to lead the clinical research which can have a significant impact on future patient care. The CBD is also the leading national center for pediatric bone marrow transplants and in developing anti-cancer immune therapies.
She is the medical director of the Oncology Outpatient clinic, an attending physician, Department of Pediatrics, Division of Oncology at the cancer center at Children’s Hospital of Philadelphia which has the largest childhood and adolescent ALL programs in the world. She uses her clinical expertise to advise on the management of relapsed patients in the innovative clinical trials open at the CHOP. She has strived to create a nationally recognized program for the treatment of relapsed hematologic malignancies at CHOP and was an integral member of the team that treated the first patient with ALL with chimeric antigen receptor T cell therapy (CART T-cell).
Children that require a specialized treatment in hematology and oncology like in leukemia, are treated through the Hematologic Malignancy Center at the Dana-Farber/Boston Children’s cancer and blood disorders center. The HMC has an integrated team of specialists like the pediatric hematologists/ oncologists, pediatric hematopathologists, surgical oncologists, stem cell transplant physicians and radiation oncologists, radiologists including experts from every pediatric medical subspecialty. The program sees more than 125 newly diagnosed patients with leukemia and lymphoma annually and continues to lead high-impact clinical trials designed to increase cure rates, decrease treatment-related toxicities and improve care for long-term survivors.
The director of the Kimmel Center’s Pediatric Leukemia Program at the Johns Hopkins Medical center in Baltimore, Dr Brown on meeting with the first few patients was blown away by the courage and maturity the kids showed and that has been the motivation for him to go to work every day ever since. Pat brown leads a number of clinical trials nationally and internationally of which one is a COG trial testing a novel drug developed at Johns Hopkins that targets mutations in a gene called FLT3. Dr. Brown co-chairs the National Comprehensive Cancer Network(NCCN) ALL panel, which has established the first national clinical practice guidelines for the treatment of adolescents and teens with ALL. His lab is performing further experiments in to optimize dosing, to develop a test that can be used to predict which patients are most likely to benefit from the new drugs and to determine how leukemia cells are able to survive despite treatment.
Dr. Wolden is a Radiation Oncologist at the Memorial Sloan Kettering Cancer Center and is a member of the pediatric, ophthalmic and bone marrow transplant disease management teams. Because radiation therapy can be sensitive to children causing long-term side effects, she approaches each patient with their unique and customized design for radiation therapy to maximize the benefits of treatment while minimizing side effects. She is also involved in numerous clinical trials for the Children’s Oncology Group and with the research on the late effects of radiation therapy with the Childhood Cancer Survivor Study.
The LLS is the world’s largest voluntary health agency dedicated to blood cancer with a mission to cure leukemia, lymphoma, multiple myeloma and improve the quality of life of patients and their families. The LLS funds lifesaving blood cancer research around the world, provides free information and support services and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.